• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [267 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2024 Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Use of structured support programmes in the monitoring of heart failure patients - an evidence map]
2024 Canary Health Service [Effectiveness, safety, and cost-effectiveness of out-of-hospital cardiac rehabilitation for ischemic heart disease or heart failure]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enalapril (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III - Addendum to Project D23-02]
2024 NIHR Health Technology Assessment programme Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation
2024 NIHR Health and Social Care Delivery Program Integrating palliative care and heart failure: the PalliatHeartSynthesis realist synthesis
2024 National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 984
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Quality indicators for the care and services provided in long-term left ventricular assist device implantation programs]
2024 National Institute for Health and Care Excellence (NICE) Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices. NICE diagnostics guidance 61
2024 Institute for Clinical Effectiveness and Health Policy (IECS) [Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2023 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with preserved ejection fraction) - Benefit assessment according to §35a Social Code Book V]
2023 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in internal medicine]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56]
2023 Health Technology Wales (HTW) Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure
2023 National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 902
2023 National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 929
2022 NIHR Health Technology Assessment programme REVascularisation of Ischaemic VEntricular Dysfunction (REVIVED): a randomised comparison of percutaneous coronary intervention (with optimal medical therapy) vs. optimal medical therapy alone for heart failure secondary to coronary disease
2022 NIHR Health Technology Assessment programme Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022 Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022 Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022 Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022 Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2022 Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022 Agency for Care Effectiveness (ACE) SGLT2 inhibitors for treating heart failure with reduced ejection fraction and chronic kidney disease
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vericiguat (cardiac failure) - Addendum to Commission A21-120]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022 National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 773
2022 National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation. NICE interventional procedures guidance 730
2022 HTA South [Cardiac Contractility Modulation device treatment in heart failure]
2021 Ontario Health Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2021 Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: long-term left ventricular assist devices, real-world evolving portrait of use and outcomes in Québec from 2010 to 2017]
2021 Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous left ventricular assist devices: micro-axial flow pumps: systematic review
2021 Health Technology Wales (HTW) Natriuretic peptides to rule-in and rule-out a diagnosis of acute heart failure in adults in the emergency department setting
2021 Institute for Clinical Effectiveness and Health Policy (IECS) [SGLT2 inhibitors in heart failure]
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice on the reassessment of tafamidis (Vyndaqel®)
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice dapagliflozin (Forxiga®) extension of further condition
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Assessment according to §137h Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Addendum to Commission A20-102]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Addendum to Commission A20-113]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Addendum to commission H20-06]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Heart failure"]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V]
2021 Canadian Agency for Drugs and Technologies in Health (CADTH) Remote monitoring programs for cardiac conditions
2021 Institute for Clinical Effectiveness and Health Policy (IECS) [Tafamidis for transthyretin amyloid cardiomyopathy]
2021 Agency for Healthcare Research and Quality (AHRQ) Automated-entry patient-generated health data for chronic conditions: the evidence on health outcomes
2021 Agency for Healthcare Research and Quality (AHRQ) Interventions to decrease hospital length of stay
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional therapy in heart failure patients with malnutrition]
2021 National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 679
2021 National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 696
2021 National Institute for Health and Care Excellence (NICE) Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2021 National Institute for Health and Care Excellence (NICE) Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure. NICE interventional procedures guidance 711
2021 National Institute for Health and Care Excellence (NICE) Permanent His-bundle pacemaker implantation for treating heart failure. NICE interventional procedures guidance 694
2020 Ontario Health Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment
2020 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure
2020 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of the left ventricular assist device (LVAD) as destination therapy in paediatric patients]
2020 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (wild-type or hereditary transthyretin amyloid cardiomyopathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 National Institute for Health and Care Excellence (NICE) Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. NICE interventional procedures guidance 677
2019 Health Technology Wales (HTW) Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of extracorporeal membrane oxygenation (ECMO) in adults in Quebec]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report]
2019 National Institute for Health and Care Excellence (NICE) Cardiac contractility modulation device implantation for heart failure. NICE interventional procedures guidance 655
2018 NIHR Health Technology Assessment programme Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study
2018 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Left ventricular assist device (LVAD) as destination therapy]
2018 Penn Medicine Center for Evidence-based Practice (CEP) Palliative care in the outpatient setting for patients with heart failure or advanced lung disease
2018 Penn Medicine Center for Evidence-based Practice (CEP) Diagnosis and treatment of gastrointestinal bleeding in patients with left ventricular assist devices
2018 Canary Health Service [Safety, effectiveness, and cost-effectiveness of subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death]
2018 Andalusian Health Technology Assessment Area (AETSA) [Cardiopoietic stem cells for the treatment of heart failure secondary to myocardial ischemia]
2018 Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure]
2017 NIHR Health Technology Assessment programme Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model
2017 NIHR Health Services and Delivery Research programme SUPPORT-HF 2 (Seamless User-centred Proactive Provision Of Risk-stratified Treatment for Heart Failure) - An internal pilot phase of a planned large-scale randomised trial of an integrated, technology-enabled care delivery model
2017 Health Quality Ontario (HQO) Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review
2017 Health Quality Ontario (HQO) Percutaneous ventricular assist devices: OHTAC recommendation
2017 Basque Office for Health Technology Assessment (OSTEBA) [Clinical effectiveness and cost-effectiveness of non-invasive telemonitoring on patients with heart failure]
2017 National Institute for Health and Care Excellence (NICE) Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. NICE interventional procedures guidance 602
2017 National Institute for Health and Care Excellence (NICE) ENDURALIFE powered CRT-D devices for treating heart failure. NICE medical technologies guidance 33
2016 Health Quality Ontario (HQO) Left ventricular assist devices for destination therapy: a health technology assessment
2016 Health Quality Ontario (HQO) Left ventricular assist devices for destination therapy: OHTAC recommendation
2016 NIHR Horizon Scanning Centre (NIHR HSC) Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft
2016 NIHR Horizon Scanning Centre (NIHR HSC) Furosemide sc2Wear micro-pump patch for oedema in heart failure
2016 Belgian Health Care Knowledge Centre (KCE) Left ventricular assist devices in the treatment of end-stage heart failure
2016 NIHR Horizon Scanning Centre (NIHR HSC) C3BS-CQR-1 (C-Cure) for heart failure secondary to ischaemic cardiomyopathy
2016 HAYES, Inc. Sacubitril-valsartan (Entresto) for heart failure
2016 Agenzia nazionale per i servizi sanitari regionali (Agenas) Implantable Left Ventricular Assist Device (LVAD) in addition to guideline directed medical therapy (GDMT) in end stage heart failure
2016 Institute for Clinical Effectiveness and Health Policy (IECS) Sacubitril in combination with valsartan for chronic heart failure